Introduction
Ovarian clear cell carcinoma (OCCC) accounts for 5–25% of all epithelial ovarian cancer (EOC) cases [
1,
2]. Reported objective response rates to conventional platinum chemotherapy in OCCC are 11.1% compared to 72.5% in high-grade serous ovarian carcinoma (HGSC) [
2,
3], representing an EOC of poorer prognosis, which is especially evident at advanced stages [
1,
4]. Clinically, OCCCs are commonly associated with endometriosis [
5], which is considered a direct precursor of clear cell carcinoma [
6] and shows a higher incidence of thromboembolic events (TEEs) [
6].
The overall frequency of OCCC in Asiatic populations (10.3–25%) [
7‐
10] is higher than that in North America (12.2%) [
11] and Europe (2–8%) [
12,
13]. The reasons for this disparity remain unknown; however, some reports suggest genetic determinants [
14]. The most frequent gene alterations in OCCC are in the
AT-rich interaction domain 1 A (
ARID1A) and
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit α (
PIK3CA) genes [
15]. Both alterations frequently coexist and occur as an early event in OCCC development [
16,
17]. Other molecular markers are used to distinguish OCCC from other EOC histotypes and include the expression of hepatocyte nuclear factor 1 homeobox B (HNF1B) and the absence of Wilms tumor protein 1 (WT1), estrogen receptor (ER) and progesterone receptor (PR) [
18]. Unlike HGSC, OCCCs usually express wild-type TP53 protein and have a much lower frequency of
BRCA1 and
BRCA2 mutations [
19].
The scarce information about genome-wide patterns of aberrations in OCCCs was obtained from studies focusing on individual cohorts with different geographical and ethnic origins [
20‐
24]. Remarkably, two of the most frequent copy number (CN) alterations found in OCCCs, i.e., amplification of chromosomes 8q and 20q13.2 (including the
ZNF217 oncogene), showed different prevalence in OCCCs with different geographical origins [
21]. To date, genome-wide CN alteration profiles of OCCCs have not been obtained for Latin American countries.
In this study, we sought to provide a comprehensive description of the molecular characteristics of ovarian clear cell carcinomas (OCCCs) from Brazil, Costa Rica, and Spain, a European country with strong cultural ties to Latin America. By integrating clinical, molecular markers, and genomic aberration data, we aim to highlight the unique features of OCCCs from under-represented geographical regions. Overall, our findings may contribute to improving outcomes for patients with OCCC and inform personalized treatment strategies.
Discussion
In the present study, the median age of diagnosis was 50 years, consistent with the earlier diagnoses of OCCCs compared to HGSC in the United States (median 55 vs. 64 years) [
3]. Moreover, OCCC was detected earlier in women with endometriosis (median = 38 years, range 31–59), which is probably connected with the fact that most of those patients were diagnosed at the initial stage [
40,
41]. To date, the most important prognostic factor for overall survival is the sensitivity to platinum-based chemotherapy, regardless of the stage of the tumor [
2]. However, for predicting progression-free survival (PFS), an advanced stage of cancer has been identified as the main prognostic factor, with the occurrence of thromboembolic events (TEEs) also contributing to the prognosis. In our cohort, we found that endometriosis did not significantly impact either OS or PFS. This is in contrast to a previous report, which suggested that endometriosis could be a prognostic factor [
42].
PIK3CA mutations are common in OCCC; accordingly, they were detected in 30% of our samples with a relatively lower frequency than reported in other populations [
37,
43‐
50]. Our cohort also showed the concomitant loss of ARID1A expression associated with
PI3KCA mutation, as previously observed [
16]; those alterations are thought to occur at an early stage in the development of OCCC due to its presence in endometriosis precursor lesions [
6]. In fact, we observed that endometriosis was more frequent in the presence of
PIK3CA mutations and that both were associated with diagnosis at the initial stage. The cohort displayed an incidence of abnormal TP53 which is consistent with previously reported incidences in other populations [
51,
52].
The genome-wide analysis of alterations by OncoScan was never used to detect CN alterations for this particular ovarian tumor type; the first studies of OCCCs were performed with aCGH, and currently, whole-exome sequencing is being performed. Despite the different reported techniques, the most common CN alterations were easily detected in our samples, including chromosome 8q and 20q13.2 amplification. The latter contains the
ZNF217 oncogene that was not associated with shorter PFS or OS (log-rank
P-value = 0.3125 and 0.5571, respectively), as suggested before [
53]. The OCCC samples were clearly separated into clusters depending on their genomic architecture (FSl, STl and Sxl) rather than on individual CN alterations. The finding that most of the polyploid samples were inside the FSl cluster and none were classified as Sxl suggests that the genomic instability associated with the FSl pattern can be related to the loss of the diploid state [
54]. Interestingly, ploidy alterations are associated with outcome in ovarian cancer, including OCCC [
55].
Amplification of
MYC was identified in 57.7% of the samples, which is consistent with previous reports (40–64%) [
20,
44,
46] and was associated with better survival. However, a concomitant loss of the chromosome 13 region containing
BRCA2, in the MB group, was associated with outstanding good OS prognosis, suggesting that a synergistic interaction might exist. In fact, loss of
BRCA2 was a recurrent alteration in the samples within our cohort with high levels of HRD. A recent article by Wang et al. proposed a classification of ovarian tumors based on genomic signatures of aberrant DNA repair mechanisms rather than on histology [
49]. In Wang et al., the subgroup H-HRD (high-HRD), characterized by enrichment of HRD signatures, showed better survival even in ovarian tumors without
BRCA1/BRCA2 mutations. Importantly, the H-HRD subgroup showed amplification of
MYC and
MECOM genes (3q26.2) [
49], the latter being within a region we identified as recurrently amplified in the HRD-sum high group of OCCC patients. In this manner, the MB OS group of OCCCs we defined is reminiscent of the H-HRD; however, in the combined study of Wang et al., most H-HRD samples were HSGC, and no OCCC was present [
49]. Our hypothesis for this observation is that when the different histotypes are studied together, the greater levels of alterations found in HGSC mask similar alterations at lower levels in the other histotypes. This is clear from the differences observed in genomic scar levels between the FSl and STl clusters, where the latter showed exaggerated levels of all HRD signatures, in particular of HRD-LOH, relative to the FSl cluster. A recent study by Pesenti et al. classified a cohort of Italian-origin stage I epithelial ovarian cancer, including OCCCs, based on their genomic instability patterns, regardless of histological subtype [
56]. The three genomic instability patterns defined by Pesenti et al. - “stable”, “unstable”, and “highly unstable” - are analogous to the Sx, FS, and ST genomic patterns, respectively, previously defined by Tan et al. [
24]. OCCCs with lower levels of genomic alterations in our cohort were more prevalent than in the study by Pesenti et al. However, differences in sample classification between the two studies may have contributed to this discrepancy.
Synthetic lethality induced by PARP inhibitors in tumor cells with HRD is supposed to be a groundbreaking therapeutic strategy [
57] in particular, for HGSC where ~ 50% of the cases have HRD [
36]. Recently, mutations in 16 HR-associated genes were tested in a Japanese cohort, and 28% of the OCCCs showed alterations, which suggests that more patients could be selected for treatment with PARP inhibitors [
58]. We observed that loss of
BRCA2 and gain of
PIK3CB genes were present in OCCCs with higher HRD-sum levels, which includes most of the cases in the FSl and STI clusters. In this manner, it would be interesting to verify what level of HRD-sum is necessary for the use of PARP inhibitors in OCCCs and to verify whether CN loss of
BRCA2 is associated with that. Furthermore, the observed CN gain of the
PIK3CB gene in HRD-sum high OCCCs might be linked to the promising results observed with the combination of inhibitors for the PI3K pathway and PARP [
59,
60]. It has been reported that ovarian cancer patients with mutations in HR-associated genes have higher platinum sensitivity and prolonged overall survival [
61]. In our cohorts, HRD-sum and CN loss of
BRCA2 were not necessarily associated with longer OS or platinum sensitivity. In fact, all the patients with concomitant gain in
MYC and loss of
BRCA2 were sensitive to platinum-based treatment, and all of them showed a better prognosis.
The majority of the cases of the poorest OS group (PS group) showed amplification of the
ASH1L gene on chromosome 1q22. This gene codes for a histone lysine methyltransferase that can mono- or di-methylate histone H3 lysine 36 (H3K36) [
62] and is part of the Trithorax group of chromatin proteins that act as epigenetic regulators [
63]. Recently, ASH1L function has been linked to leukemogenesis in mixed-lineage leukemia [
57] and acute myelogenous leukemia [
64]. Furthermore,
ASH1L gene was identified as a driver gene liver cancer [
65]. Also, congruent
ASH1L gene amplification and mRNA up-regulation was reported in hepatocellular carcinoma [
66]. Additionally, ASH1L is overexpressed in anaplastic thyroid cancer (ATC), contributing to its aggressiveness [
67]. As in other tumor types, ASH1L might be associated with OCCC biology, and since epigenetic regulators are considered important targets for cancer treatment, our observation opens a new research opportunity to define the role of ASH1L in OCCC [
68].
An important challenge in OCCC is to predict recurrence in patients diagnosed at initial stages. We identified that gains in
MAPK8 and
MKL1 genes were associated with fast progression. The
MAPK8 gene encodes the stress-activated kinase JNK1, and its activated form is associated with shorter PFS in epithelial ovarian cancer [
69]. The importance of our finding is linked to the use of JNK1 inhibitors in clinical trials for other cancers [
70] and to the eventual use of these inhibitors to control progression in OCCC. Interestingly,
MAPK8 gene gain was observed after progression of the Occ53 OCCC. At recurrence of Occ53, few alterations were conserved compared to the primary tumor, including amplification of
WNT7B and
MAPK1 oncogenes (
Supplementary Fig.S8).
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.